Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... COLORADO SPRINGS, Colo. , March 3, 2015 /PRNewswire/ ... in the development of cannabis-based medicine, today announced two ... preparation for its multiple global product launches, and CEO ... views in the Chicago HR Examiner. In ... C. Waits about leading a company in an ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "Cardiovascular Drug Delivery - Technologies, ... Drug delivery to the cardiovascular system is ... anatomy and physiology of the vascular system; it supplies ... Drugs can be introduced into the vascular system for ...
(Date:3/3/2015)... YORK , March 3, 2015  Delcath ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces that the ... completed enrollment in 2009, have been submitted for ... clinical study utilized Melphalan Hydrochloride for Injection for ...
Breaking Medicine Technology:CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 2CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 3CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 4CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist 5Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 2Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 4
... 5, 2011 OncoSec Medical Inc. (OTCBB: ONCS), ... treat solid tumor cancers, announced today the appointment ... will lead the development of the company,s proprietary ... (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... 2011 http://www.reportlinker.com/p0567542/International-Hyaluronic-Acid-Viscosupplementation-Physician-Survey-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic ... specialists were surveyed regarding their perceptions ...
Cached Medicine Technology:OncoSec Medical Appoints Engineering Leader 2OncoSec Medical Appoints Engineering Leader 3International Hyaluronic Acid Viscosupplementation Physician Survey 2011 2International Hyaluronic Acid Viscosupplementation Physician Survey 2011 3International Hyaluronic Acid Viscosupplementation Physician Survey 2011 4International Hyaluronic Acid Viscosupplementation Physician Survey 2011 5International Hyaluronic Acid Viscosupplementation Physician Survey 2011 6International Hyaluronic Acid Viscosupplementation Physician Survey 2011 7International Hyaluronic Acid Viscosupplementation Physician Survey 2011 8
(Date:3/3/2015)... (PRWEB) March 03, 2015 The first ... the National Sleep Foundation. The event brings recognition to ... over. , According to the Centers for ... problems of one form or another. Too little or ... risk of physical illness and depression, and even a ...
(Date:3/3/2015)... Today is International Ear Care Day, ... occasion to applaud and promote the launch of Make ... Organization (WHO) for stemming the threat of noise-induced hearing ... people to practice safe listening when they recreate, be ... sporting events, or engaging in other forms of entertainment. ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The number ... since 1984 to about 15%. This increases to 50% ... (Bushnik T, Cook JL, Yuzpe AA, et al. Estimating ... 27: 738-46). Dr. Jason Hitkari, a reproductive endocrinologist and ... doctor of TCM and clinical director and founder of ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 -- vRad ( ... radiology practice, today announced that Arlene Sussman, MD, a ... host a live webinar to explore how telemedicine best ... breast imaging services for women virtually anywhere. Click ... Imaging Service Line” on March 4, 2015 at 1:00 ...
(Date:3/3/2015)... Dallas, Texas (PRWEB) March 03, 2015 ... will serve as chairman of the upcoming Dallas Rhinoplasty ... 2015. The three day symposium, which is attended by ... designed to provide surgeons with detailed information on current ... and revision rhinoplasty surgery . , The ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:ASHA Applauds Launch of New WHO Campaign 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 3
... at Georgetown University Medical Center have discovered that a ... development of mammary cells by activating two critical cancer ... meeting of the American Association for Cancer Research (AACR), ... stem cells and that targeting this gene might provide ...
... Fewer and fewer people are dying after being severely ... his colleagues from Marburg University Hospital report in the ... in Germany sank continuously between 1999 and 2005, decreasing ... Deutsches rzteblatt on the trauma registry of the German ...
... Instrument Generates Real-Time In Vivo Data via Quantitative ... ... VisEn Medical, Inc., a leader,in fluorescence in vivo imaging, today announced ... FMT 2500 is based on VisEn,s,proprietary Fluorescence Molecular Tomography (FMT(TM)) technology,platform, ...
... April 14 PartnerWeekly, a SellingSource, LLC,company, ... billion-a-year cosmetics,industry with the signing of an ... makers of SensiClear, a revolutionary acne,treatment product ... the Janice,Dickinson Modeling Agency. PartnerWeekly is a ...
... community,pharmacy owners looking to pursue the pleasures of ... ApothecaryRx offers successful,independent retail pharmacy owners a smooth ... strength and independence of,the business -- and an ... ApothecaryRx pays fair market value for the ...
... the,nation,s 78 million baby boomers begin reaching age 65 ... that is too small and woefully unprepared to,meet their ... Institute of,Medicine. The report calls for bold initiatives starting ... specialists -- in the basics of,geriatric care and to ...
Cached Medicine News:Health News:Georgetown researchers find stem cell marker controls 2 key cancer pathways 2Health News:VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System 2Health News:PartnerWeekly and SensiClear(TM) Sign Online Marketing Pact 2Health News:ApothecaryRx Provides Exit Strategy for Boomer Pharmacy Businesses; Sustains Service and Communication Structure of Community Pharmacies to Improve Drug Compliance, Reduce Drug Errors 2Health News:ApothecaryRx Provides Exit Strategy for Boomer Pharmacy Businesses; Sustains Service and Communication Structure of Community Pharmacies to Improve Drug Compliance, Reduce Drug Errors 3Health News:ApothecaryRx Provides Exit Strategy for Boomer Pharmacy Businesses; Sustains Service and Communication Structure of Community Pharmacies to Improve Drug Compliance, Reduce Drug Errors 4Health News:Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... is a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with up to ... for instruments including vacuum ovens, concentrators, gel dryers, ... PEEK head resistant to chemicals and heat ...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
... critical performance for all vacuum requirements. A ... performance to suit all applications. The large, ... of proper oil levels at a glance. ... to work with all Thermo Savant SpeedVac ...
Medicine Products: